• Users Online: 134
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2018  |  Volume : 30  |  Issue : 2  |  Page : 54-57

Study of the serum level of fasting glucagon-like peptide-1 in type 2 diabetics and its relation to the glycemic profile


1 Assistant Professor of Internal Medicine Department, Faculty of Medicine, Menoufia University, Egypt
2 Assistant Professor of Clinical Pathology Department, Faculty of Medicine, Menoufia University, Egypt

Correspondence Address:
Mohamed A Korani
90 Fawzi Moaz Street, Smoha, Alexandria, 21648
Egypt
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ejim.ejim_76_17

Rights and Permissions

Background Glucagon-like peptide-1 (GLP-1) is a peptide formed of 30 amino acids. It is synthesized in and released from the enteroendocrine L cells that are present throughout the small and the large intestine. Because of the important physiological role of GLP-1 in augmenting insulin secretion, it is generally believed that GLP-1 release is deficient in type 2 diabetes mellitus (T2DM) patients. However, studies in adults have yielded conflicting results showing decreased, normal, or increased GLP-1 concentrations in prediabetics or T2DM after oral glucose or mixed meal. The aim of this work was to study the level of fasting total GLP-1 in T2DM patients and its relation to the glycemic profile. Patients and methods This study included 60 T2DM patients and 40 participants matched for age and sex as a control group, selected from the inpatient and outpatient clinics of the Internal Medicine Department in Menoufia University Hospital. After obtaining their informed consent, all participants were subjected to a full assessment of history and physical examination with estimation of BMI, insulin resistance with homeostasis model assessment-2, and investigations including fasting blood glucose (FBG), glycated hemoglobin (HbAIc), and the total fasting levels of GLP-1. Results There was no significant difference in the level of GLP-1 between T2DM patients and the controls. There were significant negative correlations between the fasting total GLP-1 and FBG, HbAIc, serum insulin, and homeostasis model assessment-2 in both the total sample and the T2DM patients. Conclusion Fasting total levels of GLP-1 are not reduced in T2DM patients and are negatively correlated with FBG, HbAIc, and insulin resistance.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed235    
    Printed32    
    Emailed0    
    PDF Downloaded73    
    Comments [Add]    

Recommend this journal